e_Buah Biblioteca Digital Universidad de Alcalá
Publication
Artículo científico (JournalArticle)
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
14 p., Background and aims: We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors.
Approach and results: We analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL-apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6 , and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A.
Conclusions: Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification., National Institutes of Health (USA), Netherlands Organization for Applied Scientific Research (TNO) (Países Bajos), Newcastle NIHR Biomedical Research Center, Czech Ministry of Health, Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER), Departamento de Industria, Transición Energética y Sostenibilidad (Gobierno Vasco), Fundación La Caixa, Unión Europea, Fondo Nacional de Desarrollo Científico y Tecnológico (Fondecyt) (Chile), Comisión Nacional de Investigación, Ciencia y Tecnología (Chile), Agencia Nacional de Investigación y Desarrollo (ANID) (Chile)
Project:
NIH / Not available R01DK123763
,
NIH / Not available R01DK119437
,
NIH / Not available HL151328
,
NIH / Not available P30DK52574
,
NIH / Not available P30DK56341
,
NIH / Not available UL1TR002345
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 SAF2017‐88041‐R
,
Ministerio de Economía y Competitividad / Severo Ochoa Excellence Accreditation SEV‐2016‐0644
,
TNO / Not available PMC13
,
TNO / Not available PMC15
,
Ministerio de Economía y Competitividad / Programa Estatal de I+D+I Orientada a los Retos de la Sociedad PI15/01132
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 PI18/01075
,
ISCIII / Programa Miguel Servet CON14/00129
,
ISCIII / Programa Miguel Servet CPII19/00008
,
EJ-GV / Not available KK‐2020
,
Fundación La Caixa / Not available HR17‐00601
,
EC / Innovative Medicines Initiative Program 777377
,
MZCR / Not available RVO‐VFN64165/2020
,
FONDECYT / Not available 1191145
,
CONICYT / Not available AFB170005
,
ANID / Not available ACE 210009
,
EC / Innovative Medicines Initiative Program 777377
,
European Commission / Horizon 2020 Framework Programme 825510